Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03331978 · ClinicalTrials.gov registry record · NA

A Randomized Controlled Trial of an Antiretroviral Treatment Adherence Intervention for HIV+ African Americans

A NA study of HIV/AIDS, sponsored by RAND.

Completed
Registry status
NA
Development phase
306
Enrollment target
1
Study location

NCT03331978 is a NA study of HIV/AIDS that has completed, run by RAND. The registered enrollment target is 306 participants, below the 33,176-participant average among 61 other HIV/AIDS trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03331978, a NA study of HIV/AIDS, has completed, sponsored by RAND.

COMPLETED
Registry status
NA
Development phase
306 participants
Enrollment target
1
Study location

Study Summary

Project Rise is a randomized controlled trial (RCT) of an innovative, culturally congruent treatment education (TE) intervention for African Americans with HIV that targets cultural and social issues contributing to health disparities.

Conditions Studied

Interventions

  • BEHAVIORAL Rise - Treatment Education

Study Locations (1)

California

  • AIDS Project Los Angeles - Los Angeles

Trial Details

FieldValue
Enrollment Target 306 participants
Start Date 2018-01-23
Est. Completion 2021-11-07
Phase NA

Sponsor

RAND

78 total trials

What the Registry Record Tells You About NCT03331978

The ClinicalTrials.gov registry entry for NCT03331978 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 306 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 33,176-participant average among 61 other HIV/AIDS trials with a reported enrollment target (99% lower). The listed sponsor is RAND, which has 78 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV/AIDS appearing as the primary indexed condition, and to 1 intervention - of which Rise - Treatment Education is the first listed.

NCT03331978 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03331978 about?

NCT03331978 is a clinical study titled "A Randomized Controlled Trial of an Antiretroviral Treatment Adherence Intervention for HIV+ African Americans". Project Rise is a randomized controlled trial (RCT) of an innovative, culturally congruent treatment education (TE) intervention for African Americans with HIV that targets cultural and social issues contributing to health disparities.

What is the current status of trial NCT03331978?

This trial is currently completed. It is a NA study. The enrollment target is 306 participants. The study started on 2018-01-23. Estimated completion is 2021-11-07.

What conditions does trial NCT03331978 study?

This clinical trial studies the following conditions: HIV/AIDS.

What interventions are being tested in trial NCT03331978?

The interventions under investigation include: Rise - Treatment Education (BEHAVIORAL).

Who is sponsoring clinical trial NCT03331978?

This trial is sponsored by RAND, which has 78 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03331978 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV/AIDS

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.